Horizon Therapeutics Public Limited (NASDAQ:HZNP) Receives $110.71 Average Target Price from Analysts

Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Free Report) has received a consensus rating of “Hold” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating. The average twelve-month target price among brokerages that have issued a report on the stock […]

Related Keywords

United Kingdom ,British , ,Horizon Therapeutics Public Limited ,Baird Financial Group Inc ,Renaissance Technologies ,Horizon Therapeutics Public Company Profile ,Horizon Therapeutics Public Limited Company ,Get Free Report ,Horizon Therapeutics Public ,Therapeutics Public ,Two Investors ,Teachers Pension Plan Board ,Baird Financial Group ,Financial Group ,Get Free ,Therapeutics Public Limited Company ,Horizon Therapeutics Public Daily ,Nasdaq Hznp ,Hznp ,Medical ,44047t10 ,Ratings ,Consensus ,